Green materials Moringa oleifera leaf powder effects to attenuate liver fibrosis development

Abstract

Liver fibrosis is the initial step of hepatocellular carcinoma (HCC). Liver fibrosis can be triggered by metabolic perturbation, viral infection, and harmful chemical exposure. This in vivo study aims to investigate the potential of Moringa oleifera leaf powder (MOLP) from Madura Island as the future candidate for antifibrosis and hepatoprotective agent. The study was conducted to evaluate the alteration of circulating levels of liver injury marker-linked liver fibrosis development, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST). The animal model was prepared using Balb-c mice age 6-8 weeks treated by intraperitoneal injection of carbon tetrachloride (CCl4) dose 1µL/g of BW for six weeks to induce liver fibrosis. The experimental groups were received green materials Moringa oleifera leaf powder solution with a serial dosage by peroral administration for six weeks. Interestingly, our animal model's preliminary study shows that the administration of green materials MOLP can alleviate the increase of ALT and AST. MOLP treatment can also prevent significant changes in liver weight, morphology, and even histological feature-associated liver injury and fibrosis. Hence, MOLP Madura Island may become the future green materials source for cancer herbal drug development.